FDA approves Polivy in combination with R-CHP for people with certain types of 1L DLBCL April 27, 2023
FDA Advisory Committee Votes In Favour of the Clinical Benefit of Polivy Combination For People With 1L DLBCL March 15, 2023
Initial Data from the Ongoing Ph 2B VITALIZE Trial in Patients with r/r DLBCL announced December 19, 2022
BLAs for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of R/R LBCL and DLBCL submitted November 2, 2022
New Long-Term Data from L-MIND Shows Durable Response to Monjuvi® (tafasitamab-cxix) for R/R DLBCL Patients October 5, 2022
